Has Devri Cashe received payments from drug or device companies?

Yes. Drug and device makers reported $8,185 in general payments to Devri Cashe across 404 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Devri Cashe did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Devri Cashe come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Devri Cashe

Family · Reading, PANPI 1912303744

Payments from drug & device makers

$8,185in general payments, 2019–2025

Across 404 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$2K
AstraZeneca$1K
Gilead$1K
Novo Nordisk$499
Merck$452
Boehringer Ingelheim$427
plus $3K from 19 others

What the payments were for

Food & beverage$8,11199%
Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	114	$1,973
AstraZeneca	37	$1,180
Gilead	56	$1,011
Novo Nordisk	19	$499
Merck	26	$452
Boehringer Ingelheim	6	$427
Amarin Pharma, Inc.	34	$412
Lilly USA, LLC	21	$296
AbbVie	13	$278
Theratechnologies Inc.	12	$273
Bayer	7	$241
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	17	$223
Johnson & Johnson	6	$173
Braeburn Inc.	4	$137
Biohaven Pharmaceutical Holding Company Ltd.	4	$110
Sanofi-aventis U.S. LLC	6	$88
Ironwood Pharmaceuticals, Inc	5	$85
Kowa Pharmaceuticals America, Inc.	4	$58
Indivior Inc.	3	$57
Amgen	3	$52
Biohaven Pharmaceuticals, Inc.	2	$52
Sunovion Pharmaceuticals Inc.	2	$47
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$24
Idorsia Pharmaceuticals US Inc	1	$19
Abbott	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,185 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JulucaDolutegravir/Rilpivirine	70	$234,404
RukobiaFostemsavir Tromethamine	22	$193,347
BiktarvyBictegrav/Emtricit/Tenofov Ala	44	$164,228
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf	32	$145,951
DescovyEmtricitabine/Tenofov Alafenam	55	$112,705
DovatoDolutegravir Sodium/Lamivudine	29	$85,189
TivicayDolutegravir Sodium	34	$76,405
FarxigaDapagliflozin Propanediol	102	$60,697
IsentressRaltegravir Potassium	31	$57,619
PrezistaDarunavir	11	$21,347
JardianceEmpagliflozin	31	$17,680
LinzessLinaclotide	26	$13,806
TrulicityDulaglutide	14	$13,677
Abacavir-LamivudineAbacavir Sulfate/Lamivudine	12	$12,552
OzempicSemaglutide	13	$12,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Viiv Healthcare CompanyJuluca, Rukobia, Dovato, Tivicay	$1,973	$589,346155 claims
GileadBiktarvy, Descovy	$1,011	$276,93399 claims
AstraZenecaFarxiga, Breztri Aerosphere	$1,180	$68,311114 claims
MerckIsentress, Januvia	$452	$66,39647 claims
Novo NordiskOzempic, Rybelsus	$499	$23,72625 claims
Boehringer IngelheimJardiance	$427	$17,68031 claims
AbbVieLinzess	$278	$13,80626 claims
Lilly USA, LLCTrulicity	$296	$13,67714 claims
Indivior Inc.Suboxone	$57	$12,16723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.